AstraZeneca's hopes for baxdrostat are high, as in early 2023 it acquired the drug by purchasing its developer -- biotech ...

A recent Lancet study reveals that Chronic Kidney Disease (CKD) has doubled globally since 1990, now affecting nearly 800 ...

Black adults living in communities with few grocery stores who participated in a grocery support program providing ...

(Alliance News) - AstraZeneca PLC on Sunday announced results from the phase 3 trial of its Baxdrostat treatment which showed a statistically significant reduction in the systolic blood pressure of ...

People in their 30s may risk a heart attack or stroke in later life even when they have "normal" blood pressure, if it's too high or steeply rising, according to a new study led by UCL researchers.

High blood pressure, also called hypertension, is a condition in which the blood force against the body’s blood vessels is consistently too high. Think of it like too much pressure in a garden hose.

Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood ...

One major cause of high systolic blood pressure is eating too much salt. Salt contains sodium, and when there is too much ...

A new aldosterone synthase inhibitor added to SGLT2 inhibitors reduces uncontrolled blood pressure in patients with chronic kidney disease, according to the results of a phase 2 trial.

A record-breaking 4,432 scientific abstracts accepted at the American Heart Association’s meeting here adorned posters, ...

AstraZeneca's aldosterone synthase inhibitor baxdrostat reduced blood pressure by 14 mmHg over 12 weeks, the pharma has said ...

Managing hypertension may lower dementia risk A new 2025 high blood pressure guideline from the American Heart Association (AHA) and the American College of Cardiology (ACC) calls for earlier ...